BBIO Q4 2022 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-85.5% YoY

Gross Profit

$1M65.4% margin

Operating Income

-$129M-6910.8% margin

Net Income

-$138M-7357.8% margin

EPS (Diluted)

$-1.04

QoQ Revenue Growth

+453.3%

Cash Flow

Operating Cash Flow

-$93M

Free Cash Flow

-$94M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$623M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.3B

Cash & Equivalents

$377M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$13M	-85.5%
Gross Profit	$1M	$11M	-89.2%
Operating Income	-$129M	-$166M	+22.0%
Net Income	-$138M	-$147M	+6.5%